Development of molecular-targeted therapy with miRNA inhibitors modifying DNA-Damage-Response

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K18465
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Japanese Foundation for Cancer Research
• Principal Investigator: Okamoto Yuka 公益財団法人がん研究会, がん化学療法センター ゲノム研究部, 研究員 (50625217)
• Research Collaborator: KOIDO Masaru 公益財団法人がん研究会, がん化学療法センター ゲノム研究部, 協力研究員
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: miRNA阻害剤 / がん細胞 / DNA損傷応答 / 抗がん治療

Outline of Final Research Achievements

MicroRNAs (miRs) are involved in generation and progression of tumor through modifying expression of target genes. This study aimed to obtain basic information and proof of concept in development of new molecular-targeted therapy using miR inhibitors. To this end, cytostatic effects brought by miR-197 inhibitor, found as a target candidate, was analyzed in detail. Evaluation of cell-line selectivity of miR-197 revealed that the cytostatic effects depended on cellular-context but not on the organ of origin. Mechanistically, miR-197 inhibitor suppressed expression of several genes that are crucial for DNA damage repair. In addition, we searched and determined anti-cancer drug that show synergistic effect with miR-197 inhibitor.

Free Research Field

腫瘍治療学、腫瘍生物学、細胞生物学